Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Akari Therapeutics, Plc AKTX
$0.18
+$0 (1.61%)
На 18:01, 12 мая 2023
+733.33%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
18200880.00000000
-
week52high
1.61
-
week52low
0.14
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.30865000
-
EPS
-0.34000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 10:59
Описание компании
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley FBR | Buy | Buy | 13 мар 2020 г. |
| B. Riley FBR | Neutral | 05 мая 2018 г. | |
| Canaccord Genuity | Buy | Buy | 29 мар 2018 г. |
| B. Riley FBR | Neutral | 08 февр 2018 г. | |
| William Blair | Outperform | Market Perform | 22 сент 2017 г. |
| Alliance Global Partners | Buy | 01 ноя 2022 г. | |
| HC Wainwright & Co. | Buy | 05 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Byrne David | A | 1300000 | 1300000 | 29 июн 2016 г. |
| Ungar Stuart | A | 1300000 | 1300000 | 29 июн 2016 г. |
| Cohen Mark S | A | 1300000 | 1300000 | 29 июн 2016 г. |
| Williams Donald Allen | A | 1300000 | 1300000 | 29 июн 2016 г. |
| Hill James | A | 1300000 | 1300000 | 29 июн 2016 г. |
| Byrne David | A | 1300000 | 1300000 | 22 апр 2016 г. |
| SHAW ROBERT M | A | 1800000 | 1800000 | 23 мар 2016 г. |
| Shaw Allan | A | 1068722 | 1068722 | 25 ноя 2015 г. |
| Hill James | A | 1068722 | 1068722 | 25 ноя 2015 г. |
| Cohen Mark S | A | 1028722 | 1028722 | 25 ноя 2015 г. |
Новостная лента
Akari Therapeutics to Present at Biotech Showcase™ 2023
GlobeNewsWire
04 янв 2023 г. в 08:00
NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akari's two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), for the treatment of severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program investigating long-acting PAS-nomacopan as a potential treatment for geographic atrophy.
Akari Therapeutics (AKTX) Stock: Why It 27.88%
Pulse2
13 сент 2022 г. в 05:58
The stock price of Akari Therapeutics (AKTX) fell by 27.88% in the most recent trading session. This is why.